News

June 2015

Nicotinamide Reduces Skin Cancer Risk

New research shows that taking 500 mg of nicotinamide (vitamin B3) by mouth twice daily for one year reduces the risk of developing non-melanoma skin cancer in people who have already had common skin cancers such as basal cell carcinoma and squamous cell carcinoma. Nicotinamide might be beneficial for people who are at high risk of developing common skin cancers, particularly because it is very accessible and inexpensive. It does not appear to reduce melanoma skin cancer risk.

For more information about nicotinamide (vitamin B3), view our complete scientific monograph.

References

  1. Martin AJ, Chen A, Choy B, et al. Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial. J Clin Oncol 33, 2015 (suppl; abstr 9000)

The information in this brief report is intended for informational purposes only, and is meant to help users better understand health concerns. This information should not be interpreted as specific medical advice. Users should consult with a qualified healthcare provider for specific questions regarding therapies, diagnosis and/or health conditions, prior to making therapeutic decisions. Copyright © 2024 NatMed. Commercial distribution or reproduction prohibited. NatMed is the leading provider of high-quality, evidence-based, clinically-relevant information on natural medicine, dietary supplements, herbs, vitamins, minerals, functional foods, diets, complementary practices, CAM modalities, exercises and medical conditions. Monograph sections include interactions with herbs, drugs, foods and labs, contraindications, depletions, dosing, toxicology, adverse effects, pregnancy and lactation data, synonyms, safety and effectiveness.